^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aybintio (bevacizumab biosimilar)

    i
    Other names: SB8, SP-8
    Company:
    3SBio, Mundipharma, Samsung
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    29d
    Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial • Combination therapy • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical
    1m
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> May 2025 | Trial primary completion date: Jan 2025 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2ms
    Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (clinicaltrials.gov)
    P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • docetaxel • Aybintio (bevacizumab biosimilar) • MK-4830
    4ms
    Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (clinicaltrials.gov)
    P3, N=880, Not yet recruiting, NRG Oncology
    New P3 trial
    |
    BRCA (Breast cancer early onset)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Aybintio (bevacizumab biosimilar) • Avzivi (bevacizumab-tnjn)
    4ms
    External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1/2 trial • Metastases
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    12ms
    Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Oct 2024 --> Dec 2023
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • docetaxel • Aybintio (bevacizumab biosimilar) • MK-4830
    1year
    Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2024
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • docetaxel • Aybintio (bevacizumab biosimilar) • MK-4830
    over1year
    BRISK: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (clinicaltrials.gov)
    P2, N=32, Recruiting, Asan Medical Center
    New P2 trial • Metastases
    |
    FH (Fumarate Hydratase)
    |
    Avastin (bevacizumab) • erlotinib • Aybintio (bevacizumab biosimilar)